Compare THG & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THG | BLCO |
|---|---|---|
| Founded | 1852 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Ophthalmic Goods |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.0B |
| IPO Year | 1996 | 2022 |
| Metric | THG | BLCO |
|---|---|---|
| Price | $176.73 | $16.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $194.60 | $18.45 |
| AVG Volume (30 Days) | 265.4K | ★ 417.4K |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.11% | N/A |
| EPS Growth | ★ 55.21 | N/A |
| EPS | ★ 18.16 | N/A |
| Revenue | ★ $6,594,400,000.00 | $5,101,000,000.00 |
| Revenue This Year | $3.04 | $8.63 |
| Revenue Next Year | $4.24 | $5.58 |
| P/E Ratio | $9.89 | ★ N/A |
| Revenue Growth | 5.72 | ★ 6.47 |
| 52 Week Low | $155.93 | $10.45 |
| 52 Week High | $188.18 | $18.92 |
| Indicator | THG | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 55.62 | 49.85 |
| Support Level | $173.68 | $16.35 |
| Resistance Level | $177.72 | $16.81 |
| Average True Range (ATR) | 3.52 | 0.47 |
| MACD | 0.85 | 0.11 |
| Stochastic Oscillator | 60.43 | 72.63 |
The Hanover Insurance Group Inc is a holding company whose primary business is offering property and casualty insurance products and services. The company markets itself through independent agents and brokers in the United States while conducting business through Hanover Insurance, Citizens and other THG subsidiaries. The company conducts business operations through four operating segments: Core Commercial, Specialty, Personal Lines, and Other. The company operates an investment portfolio that is exposed to fixed-income securities.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.